TEL: 044-952-0102


Global Heparin Market 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 254966
出版日 ページ情報 英文 73 Pages
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
ヘパリンの世界市場:2016~2020年 Global Heparin Market 2016-2020
出版日: 2016年03月17日 ページ情報: 英文 73 Pages

ヘパリンは好塩基球および肥満細胞によってつくられる抗凝血剤です。すでに形成された血栓には有効ではありませんが、体内の血栓を溶解することができます。また、豚の腸や牛の肺から抽出・製造された薬品を投与することで、対外から摂取することもできます。ヘパリンは分画の程度により、UFH LMWH ULMWHの3種類に分類され、症状に応じて使い分けられています。世界のヘパリン市場は、2016~2020年にかけて4.74%のCAGR (複合年間成長率) となる見込みです。


第1章 エグゼクティブ・サマリー

  • 調査結果の概略

第2章 調査範囲

  • 調査概要
  • 大手ベンダーの主要製品

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略
  • 主な購入基準

第5章 ヘパリン:概要

  • 作用機序 (MOA)
  • ヘパリン使用の限界
  • ヘパリンの臨床での使用
  • ブランド薬のプロファイル

第6章 パイプライン製品のポートフォリオ

  • LMWヘパリンMMX
  • URG101
  • ヘパリン
  • ヘパリンおよびデオキシリボヌクレアーゼ (DNAse)
  • ヘパリンおよび他の吸入薬

第7章 市場環境

  • 世界の血液凝固阻止薬の市場
  • 世界のヘパリン市場
  • ファイブフォース分析

第8章 ヘパリンのCPB手術での使用

  • CPB (心肺バイパス)
  • ヘパリンのCPB手術での使用
  • CPB手術向けヘパリンの世界市場

第9章 ヘパリンAPI (原薬) の市場

  • 中国:ヘパリンAPIの市場

第10章 粗ヘパリンのサプライヤー

  • FDAのサプライヤー向けガイドライン

第11章 製品の種類別の市場区分

  • UFH (未分画ヘパリン)
  • LMWH (低分子量ヘパリン)
  • ULMWH (超低分子量ヘパリン)

第12章 投与経路 (ROA) 別の市場区分

  • 静脈内 (IV) 注射/注入
  • 皮下 (SC) 注射

第13章 地域区分

  • 世界のヘパリン市場:地域別の詳細動向 (今後6年間分)
  • 欧州・中東・アフリカ諸国 (EMEA) 市場
  • 南北アメリカ市場
  • アジア太平洋地域市場

第14章 市場成長促進因子

  • 関連疾患の有病者数の増加
  • 粗ヘパリンのサプライチェーンの拡大
  • 米国FDA (食品医薬品局) によるウシヘパリンの再導入

第15章 促進因子とその影響

第16章 市場の課題

  • 特許満了に伴う、ジェネリック製品の集中的利用
  • 副作用のリスク
  • 粗ヘパリンの不足
  • 粗悪品の脅威
  • すでに普及している経口抗凝血剤の存在

第17章 促進因子と課題の影響

第18章 市場動向

  • 新たな治療用途の開拓の見通し
  • 戦略的提携
  • 研究開発 (R&D) の活発化
  • 新たなヘパリン解毒剤の上市

第19章 ベンダー環境

  • 競合シナリオ
  • 市場分析
  • Sanofi
  • Pfizer
  • Aspen
  • LEO Pharma
  • その他の有力ベンダー

第20章 付録

  • 略語リスト

第21章 Technavioについて


  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for heparin drugs
  • Exhibit 03: Differences between porcine heparin and bovine heparin
  • Exhibit 04: Process of blood coagulation
  • Exhibit 05: Mechanism of action of heparin
  • Exhibit 06: Pipeline portfolio: Heparin drugs
  • Exhibit 07: Market share of global heparin market in global anticoagulant drugs market 2015
  • Exhibit 08: Global anticoagulant drugs market 2015-2020 ($ billions)
  • Exhibit 09: Global heparin market 2015-2020 ($ billions)
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Global heparin market in CPB surgeries 2015-2020 ($ millions)
  • Exhibit 12: Process of crude heparin production in China
  • Exhibit 13: Segmentation of global heparin market by product type 2015
  • Exhibit 14: Segmentation of global heparin market by ROA
  • Exhibit 15: Segmentation of global heparin market based on geography 2015
  • Exhibit 16: Global heparin market revenue by geography 2015-2020 ($ billions)
  • Exhibit 17: Global heparin market by geography 2015-2020
  • Exhibit 18: Heparin market in EMEA 2015-2020 ($ billions)
  • Exhibit 19: Heparin market in Americas 2015-2020 ($ billions)
  • Exhibit 20: Heparin market in APAC 2015-2020 ($ billions)
  • Exhibit 21: Global heparin market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 22: Impact of drivers
  • Exhibit 23: Impact of drivers and challenges
  • Exhibit 24: Sanofi: YoY revenue and growth rate of Lovenox 2013-2015 ($ billions)
  • Exhibit 25: Geographical segmentation of Lovenox 2015
  • Exhibit 26: Sanofi: Key takeaways
  • Exhibit 27: Pfizer: YoY revenue and growth rate of Fragmin 2013-2015 ($ millions)
  • Exhibit 28: Geographical segmentation of Fragmin by revenue 2015
  • Exhibit 29: Pfizer: Key takeaways
  • Exhibit 30: Aspen: Key takeaways
  • Exhibit 31: LEO Pharma: Key takeaways
Product Code: IRTNTR9053

About Heparin

Heparin, a disaccharide anticoagulant or blood thinner, prevents the formation of blood clots. It is produced in the body by basophils and mast cells. It is stored within mast cells and secreted at the injury site. Though it has no effect on already formed clots, it enables the body's natural clot lysis mechanisms to dissolve clots. It can also be taken from outside as a drug. Heparin can be derived from natural sources such as pig intestine and bovine lungs.

Heparin is divided into two types based on the fractionation process. Both types have medical use, with the selection done based on preference for a particular condition.

UFH: It is directly obtained from natural sources, without undergoing any fractionation.

LMWH: It is derived by depolymerizing UFH. The pharmacodynamics properties of LMWH are more predictable when compared to UFH.

Apart from these, another category of molecules, ULMWH are available. They are structurally related to LMWHs, but differ in the composition of monosaccharides and oligosaccharides. Therefore, they have different average molecular weights from LMWH.

Technavio's analysts forecast the global heparin market to grow at a CAGR of 4.74% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global heparin market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generics used to treat disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Heparin Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline plc (GSK)
  • Leo Pharma A/S
  • Pfizer Inc.
  • Sanofi

Other Prominent Vendors

  • Alchemi
  • Baxter
  • BMS
  • Boehringer Ingelheim
  • Celgene
  • Cosmo Pharmaceuticals
  • Dr.Reddy's Laboratories
  • Eisai
  • Fresenius
  • GSK
  • Hospira
  • Laboratorios Rovi Pharmaceuticals
  • Lee's Pharmaceutical
  • Momenta Pharmaceuticals
  • Mylan
  • Novartis
  • Ockham Biotech
  • Perospher
  • PolyMedix
  • Portola Pharmaceutical
  • ProStrakan Group
  • Sagent Pharmaceticals
  • Sigma Tau Pharmaceuticals
  • UCB
  • Urigen Pharmaceuticals

Market driver

  • Growing prevalence of diseases
  • For a full, detailed list, view our report

Market challenge

  • Extensive use of generic products due to patent expirations
  • For a full, detailed list, view our report

Market trend

  • Expected exploitation of new therapeutic use
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Heparin: An overview

  • Mechanism of action (MOA)
  • Limitations of heparin use
  • Clinical uses of heparin
  • Branded drug profiles

PART 06: Pipeline portfolio

  • LMW Heparin MMX
  • URG101
  • Heparin
  • Heparin plus dexoyribonuclease (DNAse)
  • Heparin plus other inhaled drug

PART 07: Market landscape

  • Global anticoagulant drugs market
  • Global heparin market
  • Five forces analysis

PART 08: Heparin use in CPB surgery

  • CPB
  • Heparin use in CPB surgery
  • Global heparin market in CPB surgeries

PART 09: Heparin API market

  • China: Heparin API market

PART 10: Suppliers of crude heparin

  • FDA guidance for heparin suppliers
  • PART 11: Market segmentation by product type
  • UFH
  • LMWH

PART 12: Market segmentation by ROA

  • IV injection/infusion
  • SC injection

PART 13: Geographical segmentation

  • Global heparin market by geographical segmentation 2015-2020
  • Heparin market in EMEA
  • Heparin market in Americas
  • Heparin market in APAC

PART 14: Market drivers

  • Growing prevalence of diseases
  • Increase in supply chains of crude heparin
  • Reintroduction of bovine heparin by US FDA

PART 15: Impact of drivers

PART 16: Market challenges

  • Extensive use of generic products due to patent expirations
  • Risk of side-effects
  • Shortage of crude heparin
  • Threat of adulteration
  • Presence of well-established oral anticoagulants

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Expected exploitation of new therapeutic use
  • Strategic alliances
  • Increase in R&D
  • Entry of new heparin antidotes

PART 19: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Sanofi
  • Pfizer
  • Aspen
  • LEO Pharma
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

Back to Top